Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics

Trends Microbiol. 2021 Sep;29(9):836-848. doi: 10.1016/j.tim.2021.01.014. Epub 2021 Feb 19.

Abstract

Besides its prominent role in cell proliferation, cyclin-dependent kinases (CDKs) are key players in viral infections as both DNA and RNA viruses modify CDK function to favor viral replication. Recently, a number of specific pharmacological CDK inhibitors have been developed and approved for cancer treatment. The repurposing of these specific CDK inhibitors for the treatment of viral infections may represent a novel effective therapeutic strategy to combat old and emergent viruses. In this review, we describe the role, mechanisms of action, and potential of CDKs as antiviral drug targets. We also discuss the current clinical state of novel specific CDK inhibitors, focusing on their putative use as antivirals, especially against new emerging viruses.

Keywords: CDK; HIV; SARS-CoV-2; drug repurposing; viral infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment*
  • Cyclin-Dependent Kinases / antagonists & inhibitors*
  • Cyclin-Dependent Kinases / physiology
  • Drug Repositioning
  • Humans
  • SARS-CoV-2 / drug effects*
  • Virus Diseases / drug therapy*
  • Virus Diseases / enzymology

Substances

  • Antiviral Agents
  • Cyclin-Dependent Kinases